Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies.

Autor: Berger S; Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. Saskia.Berger@ukdd.de.; Hospital Pharmacy, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstrasse 74, 01307, Dresden, Germany. Saskia.Berger@ukdd.de., Moseholm KF; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark., Hegelund ER; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark., Tesch F; Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany., Nguyen MCS; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark., Mortensen LH; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark., Jensen MK; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark.; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Schmitt J; Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany., Mukamal KJ; Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Drugs & aging [Drugs Aging] 2024 May; Vol. 41 (5), pp. 423-430. Date of Electronic Publication: 2024 Apr 12.
DOI: 10.1007/s40266-024-01112-1
Abstrakt: Background and Objective: Preliminary evidence suggests a possible preventive effect of tumor necrosis factor-α inhibitors (TNFi) on incident dementia. The objective of the analysis was to investigate the association between TNFi and the risk of incident dementia in a population undergoing treatment for rheumatological disorders.
Methods: We followed patients aged ≥ 65 years with dementia and rheumatological conditions in two cohort studies, DANBIO (N = 21,538), a Danish clinical database, and AOK PLUS (N = 7112), a German health insurance database. We defined incident dementia using diagnostic codes and/or medication use and used Cox regression to compare the associations of TNFi with other rheumatological therapies on the risk of dementia. To ensure that the patients were receiving long-term medication, we included patients with rheumatic diseases and systemic therapies.
Results: We observed similar trends towards a lower risk of dementia associated with TNFi versus other anti-inflammatory agents in both cohorts (hazard ratios were 0.92 [95% confidence interval 0.76, 1.10] in DANBIO and 0.89 [95% confidence interval 0.63, 1.24] in AOK PLUS, respectively).
Conclusions: Tumor necrosis factor-α inhibitors may decrease the risk of incident dementia although the association did not reach statistical significance in this analysis. Further research, ideally with randomization, is needed to gauge the potential of repurposing TNFi for dementia prevention and/or treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: